Loading stock data…
$27.89-0.35 (-1.24%)
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Harrow, Inc. in the Healthcare sector is trading at $27.89 with a market capitalization of $1.3B. Wall Street consensus targets $65.00 (9 analysts), implying a +133.1% move over the next 12 months. The stock is currently near its 52-week low of $27.00, remaining 29.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: RSI 6 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $70.66M↑ | $44.20M↓ | $89.09M↑ | $71.64M↑ | $63.74M |
| Gross Profit | $50.36M↑ | $27.05M↓ | $70.62M↑ | $53.93M↑ | $47.51M |
| Operating Income | -$11.01M↑ | -$22.08M↓ | $15.59M↑ | $14.75M↑ | $11.41M |
| Net Income | -$17.27M↑ | -$27.60M↓ | $6.63M↑ | $1.02M↓ | $5.00M |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers Imprimis...